7tm Pharma

	Contact
	Téléphone : Mail : Adresse : 7TM PHARMA A/S Fremtidsvej 3 Hørsholm Danemark Web : http://www.7tm.com

	Consultez cette fiche en intégralité ?
	Consultez cette fiche et près de 50 000 autres fiches de Centres de Recherche dans plus de 30 pays européens sur Expernova.com ! Inscrivez-vous ou contactez-nous pour une démonstration personnalisée. Il s’agit de votre centre de Recherche ? Inscrivez-vous gratuitement et complétez vos informations.

	Profil scientifique partiel

	Quelques documents de 7tm Pharma
	Further improvement of radiotherapy of cancer through side effect reduction by application of adult stem cell therapy FIRST 2004 - 2007 Sujets : Innovation, Technology Transfer, Scientific Research, Life Sciences, Medicine, Health, Biotechnology Other Indexes:Adults stem cell therapy,cancer therapy,induced complications,Radiation,Radiation-induced complications Type de contrat : Marie Curie actions-Incoming International Fellowships Participants : UNIVERSITY HOSPITAL GRONINGEN/UNIVERSITY MEDICAL CENTER GRONINGEN NEDERLAND UNIVERSITY HOSPITAL GRONINGEN/UNIVERSITY MEDICAL CENTER GRONINGEN DEPARTMENT OF RADIATION AND STRESS CELL BIOLOGY, FACULTY OF MEDICAL SCIENCES, UNIVERSITY OF GRONINGEN, NORMAL TISSUE RADIOBIOLOGY DEPARTMENT OF STEM CELL BIOLOGY AND RESEARCH OFFICE; FACULTY OF MEDICAL SCIENCES; UNIVERSITY OF GRON PO Box 30001 Hanzeplein 1 NEDERLAND 7TM PHARMA DANMARK 7TM PHARMA Industry 7TM PHARMA A/S Fremtidsvej 3 DANMARK COMMISSARIAT À L'ENERGIE ATOMIQUE' FRANCE COMMISSARIAT À L'ENERGIE ATOMIQUE' DÉPARTEMENT DE RADIOBIOLOGIE ET RADIOPATHOLOGIE SERVICE DE GÉNOMIQUE FONCTIONNELLE rue de la Fédération 31-33 FRANCE UNIVERSITE FRANÇOIS RABELAIS FRANCE UNIVERSITE FRANÇOIS RABELAIS UNIVERSITE FRANCOIS RABELAIS/FACULTE DE MEDECINE / LABORATOIRE D'HEMATOPOIESE' 3 rue des Tanneurs FRANCE THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD UNITED KINGDOM THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD Education CANCER AND RADIOBIOLOGY RESEARCH GROUP, RESEARCH INSTITUTE University Offices, Wellington Square UNITED KINGDOM LEIDEN UNIVERSITY MEDICAL CENTER NEDERLAND LEIDEN UNIVERSITY MEDICAL CENTER DEPARTMENT OF CLINICAL ONCOLOGY, LEIDEN UNIVERSITY MEDICAL CENTER, LABORATORY FOR EXPERIMENTAL RADIOTHERAPY DEPARTMENT OF CARDIOLOGY PO Box 9600 Albinusdreef 2 NEDERLAND UNIVERSITY OF TECHNOLOGY, DRESDEN, MEDICAL FACULTY CARL GUSTAV CARUS DEUTSCHLAND UNIVERSITY OF TECHNOLOGY, DRESDEN, MEDICAL FACULTY CARL GUSTAV CARUS DEPARTMENT OF RADIOTHERAPY AND RADIATION ONCOLOGY/RADIOBIOLOGY LABORATORY Fetscherstrasse 74 DEUTSCHLAND 7TM PHARMA Denmark 7TM PHARMA Industry 7TM PHARMA A/S Fremtidsvej 3 Denmark Hide objective Radiotherapy is the second most important treatment modality after surgery in the treatment of cancer. At the present over 50 % of all cancer patients receive radiotherapy at one stage in their course. Inevitably normal tissues are exposed to ionising radiation during radiotherapy of tumours. This can result in organ failure and hence seriously can limit the treatment dose. Reduction of the side effects of radiotherapy will not only increase the quality of life after the treatment but may also result in increased survival of cancer patients as it will allow dose-escalation to the tumour. This is true even if the most optimal physical dose-delivery (conformal therapy, protons) of radiation is applied. Radiation-induced organ failure is mainly caused by stem cell sterilisation, leading to a reduced reconstitution of functional cells. Replenishment of the depleted stem cell compartment should allow regeneration of irradiated tissues. Multipotent stem cells have now been shown to reside in multiple adult tissues. The innovative vision of this project is to reduce radiation-induced complications through stem cell therapy. Hereto, bone marrow derived stem cells will be isolated, mobilised and characterised. Thus obtained stem cells will be tested for their capability to ameliorate radiation-induced complications in organs affected by radiotherapy. After completion of the project (at 24months) the obtained scientific and (bio) technological knowledge and expertise on stem cells and radiation must have established the potential of stem cell therapy to restore normal tissue functioning after irradiation. This should set the stage for the second phase of the project (25-60 months) in which methods are further improved and, importantly, late responding tissues are included. A successful replacement of stem cells and subsequent amelioration of radiation-induced complications may open theroad to completely new strategies in radiotherapy. Source : cordis